News

IC Targets AS announced that the Norwegian Patent Office approved a patent for granting covering a method determining the manganese ion uptake rate constant to indicate cardiomyocyte T-tubule density. The patent is valid until the end of 2043.

IC Targets AS announced dosing of first participants with mangafodipir in a Phase 2A trial assessing myocardial calcium channel activity with mangafodipir-enhanced Magnetic Resonance Imaging (MRI).

Results from a preclinical animal study, using manganese-enhanced MRI (MEMRI) to assess the rate of manganese uptake in cardiomyocytes in vivo, are presented at the bi-annual Contrast Media Research (CMR) Symposium in Oslo, Norway.

Results from a preclinical study, using manganese-enhanced MRI (MEMRI) to assess the rate of manganese uptake in cardiomyocytes in vivo, are presented at the annual European Congress of Radiology (ECR) conference in Vienna, Austria.

IC Targets AS strengthens its team

On 11th June 2021 the Research Council of Norway announced that IC Targets AS is among the few selected companies out of 232 applicants whose grants were awarded under the call “Innovation Project for the Industrial Sector 2021”

Proceeds from the private placement of shares completed in August 2017 provided IC Targets AS with funding for entering into an exclusive worldwide license.